Atrial fibrosis underlying atrial fibrillation (Review)

CHANG YI LI[1,2*], JING RUI ZHANG[1*], WAN NING HU[2] and SONG NAN LI[1]

[1]Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029; [2]Department of Cardiology, Laboratory of Molecular Biology, Head and Neck Surgery, Tangshan Gongren Hospital, Tangshan, Hebei 063000, P.R. China

Abstract. Atrial fibrillation (AF) is one of the most common tachyarrhythmias observed in the clinic and is characterized by structural and electrical remodelling. Atrial fibrosis, an emblem of atrial structural remodelling, is a complex multifactorial and patient-specific process involved in the occurrence and maintenance of AF. Whilst there is already considerable knowledge regarding the association between AF and fibrosis, this process is extremely complex, involving intricate neurohumoral and cellular and molecular interactions, and it is not limited to the atrium. Current technological advances have made the non-invasive evaluation of fibrosis in the atria and ventricles possible, facilitating the selection of patient-specific ablation strategies and upstream treatment regimens. An improved understanding of the mechanisms and roles of fibrosis in the context of AF is of great clinical significance for the development of treatment strategies targeting the fibrous region. In the present review, a focus was placed on the atrial fibrosis underlying AF, outlining its role in the occurrence and perpetuation of AF, by reviewing recent evaluations and potential treatment strategies targeting areas of fibrosis, with the aim of providing a novel perspective on the management and prevention of AF.

Contents

1. Introduction
2. Cardiac fibroblasts, myofibroblasts and ECM

Correspondence to: Professor Wan Ning Hu, Department of Cardiology, Laboratory of Molecular Biology, Head and Neck Surgery, Tangshan Gongren Hospital, 27 Wenhua Road, Lubei, Tangshan, Hebei 063000, P.R. China
E-mail: huwanning1212@sina.com

Dr Song Nan Li, Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, 2 Anzhen Road, Chao Yang, Beijing 100029, P.R. China
E-mail: lisongnan@ccmu.edu.cn

*Contributed equally

3. Risk factors involved in atrial fibrosis
4. Ventricular fibrosis in AF
5. Atrial fibrosis and stroke risk in AF
6. Treatment approaches targeting atrial fibrosis
7. Conclusion and future perspectives

1. Introduction

Atrial fibrillation (AF) decreases the quality of life of patients whilst also presenting as a financial burden, due to its severe complications (1). Although significant progress has been made in the treatment options that are available for management of AF, such as drugs and catheter ablation, there are complications associated with these strategies, and they are hampered by low long-term success rates. An improved understanding of the fundamental mechanisms underlying the development of AF and subsequent atrial remodelling may facilitate the development of novel and more effective therapeutic approaches for AF treatment. However, the mechanisms underlying AF are complex, and include structural and electrical remodelling, autonomic nervous system dysfunction (2) and dysregulated calcium homeostasis/handing (3). Atrial structural remodelling is the key factor linking all the AF-related mechanisms, and atrial fibrosis is the most prominent feature of atrial structural remodelling (4), but an in-depth understanding of the molecular mechanisms underlying this process has not yet been fully elucidated. For this reason, in the present review, the body of knowledge regarding AF pathophysiology, as well as the involvement of atrial fibrosis in the initiation and perpetuation of AF, were reviewed, and the available fibrosis-guided approaches for prevention and management of AF are discussed (Fig. 1).

As mentioned above, atrial fibrosis is an hallmark of atrial structural remodelling, characterized by the aberrant activation, proliferation and differentiation of fibroblasts, and subsequent excessive synthesis and irregular deposition of extracellular matrix (ECM) proteins, which have been identified as substrates of AF, and are involved in the initiation and perpetuation of AF (5). Atrial fibrosis can be divided into two types, reactive and reparative fibrosis (6,7). Reactive fibrosis is a response to cardiac inflammation or pressure overload, and can be divided into perivascular and interstitial fibrosis (8). Reparative fibrosis occurs due to the loss of cardiomyocytes, with myocardial infarction being the most cause (8). Various pro-fibrotic stimulants activate

fibroblasts to proliferate and differentiate into secretory myofibroblasts, often accompanied by the upregulation of matrix metalloproteinases (MMPs) and downregulation of tissue inhibitors of metalloproteinases (TIMPs). These abnormalities result in an imbalance in ECM deposition and degradation in the intervascular space and myocardial interstitium, ultimately altering the cardiac ultrastructure (8,9). The primary benefit of fibrosis is to maintain the integrity of the heart. However, these collagen-based scars can form barriers to electrical conduction and separate the well-connected syncytium, thereby directly interfering with conduction (10). In addition to physical uncoupling, the membrane of fibroblasts and myofibroblasts can fuse with that of cardiomyocytes to form gap junctions via connexins 40, 43 and 45 (Cx40, Cx43 and Cx45) (11,12). Despite the passive electrophysiological qualities of fibroblasts and myofibroblasts, they have a lower membrane potential than atrial resting potential and can act as an electrical source during their resting phase and as a sink during their activation, thereby reducing the conduction speed and maximum level of depolarization of action potentials (13). It has also been reported that cross-linked collagen between cardiomyocyte bundles forms a thick insulating layer that increases longitudinal conduction velocity, which is also associated with the occurrence of AF (14). When sufficient fibroblasts/myofibroblasts-cardiomyocytes interactions are formed, the arrhythmogenic mechanisms are fulfilled (15). Pathological coupling escalates the spontaneous depolarization during phase 4, and this favours triggered activity (15). Anatomical barriers decrease conduction velocity and increase conduction heterogeneity, as well as the dispersion of refractoriness, which favours re-entry (13). The interactions between triggered activity and arrhythmogenic substrates allows for the occurrence and perpetuation of AF (Fig. 2).

2. Cardiac fibroblasts, myofibroblasts and ECM

In total, four types of cells, namely endothelial cells, cardiomyocytes, fibroblasts and smooth muscle cells, make up a large proportion of cardiac cells (16). Fibroblasts are the second largest population of non-myocyte cells in the heart, accounting for ~10% of cardiac cells, and are the primary source of ECM (17). Cardiomyocytes are predominant in volume, and are the primary constituents of the heart (18). The distribution of cardiac fibroblasts in the atrium is higher than that in the ventricles, and the responses of atrial fibroblasts to pro-fibrotic stimuli are different from those of ventricular fibroblasts, which may account for the difference in the degree of fibrosis between atriums and ventricles under similar pathological conditions (19,20).

Cardiac fibroblasts are flat, spindle-shaped cells that are generally considered to have a mesenchymal origin, and they determine the homeostasis of ECM (21). During the development of the heart, most cardiac fibroblasts are differentiated from epicardium-derived cells (22). The rest are derived from the endocardium and the neural crest, which are primarily located in the interventricular septum and right atrium, respectively (Fig. 2) (23,24). Under homeostatic conditions, fibroblasts remain dormant. Apart from the activation and proliferation of resident fibroblasts, several cell linages, such as endothelial cells, bone marrow progenitor cells, circulating fibrocytes and monocytes, can differentiate into fibroblasts when activated by pathological stimulants, thus, markedly increasing the number of cardiac fibroblasts (25,26). Activated fibroblasts then synthesize not only a variety of ECM proteins, but also proteolytic enzymes that modify these proteins and can differentiate into myofibroblasts, which are contractile cells with a more potent ability to synthesize more ECM proteins (27). This differentiation causes disequilibrium in the synthesis and degradation of ECM proteins, ultimately leading to an arrhythmogenic atrial substrate (28).

The ECM not only acts as a scaffold for all cells in the heart, but it is also involved in regulating cardiac function and mediating extracellular signal transmission (29). In addition to collagens, proteoglycans, glycoprotein and other proteins (such as MMPs and TIMPs) are necessary components of the ECM (30). There are also non-glycosylated proteins and soluble components within the extracellular space, such as dermatopontin, transforming growth factor β (TGF-β) and interleukins (ILs), which are involved in the regulation of ECM remodelling (31). Of these, collagens (primarily types I and III) are the predominant constituents of the cardiac ECM (5). The synthesis of collagens starts when their progenitors, pro-collagens, are cleaved by procollagen C-terminal proteinase and procollagen N-terminal proteinase at the C- and N-terminal domains to form mature collagen molecules (9). The final step is self-assembly and cross-linking of mature collagen molecules form collagen fibres. In this enzymatic process, some proteolytic products, such as N-terminal pro-peptide of procollagen type III and C-terminal pro-peptide of procollagen type I, are released into the blood and can be used as biomarkers to assess cardiac fibrosis and evaluate AF recurrence (32-34). The process of ECM protein synthesis is a dynamic and balanced process under the fine regulation of proteolytic enzymes and their inhibitors (9). Amongst these enzymes, the most important are the MMP family members of which there are >25. They can not only degrade almost all ECM proteins, but also cytokines and growth factors, amongst other molecules, which affects the synthesis of ECM (35). Increased expression of MMP-9 has been observed in the atrial tissue and blood serum of patients with AF, and the MMP-9 levels appear to be associated with the stage of AF (36,37). In addition, it was found that serum MMP-9 levels can also be used as an independent factor to predict the recurrence of AF following catheter ablation (38). A previous meta-analysis demonstrated that the enhanced MMP-1 mRNA expression and decreased serum TIMP-2 levels may act as predictive markers for the incidence of AF (39). In addition, MMP-2 was also shown to be associated with an increased risk of AF, and may be used to identify patients that are most likely to benefit from rhythmic control strategies (40).

3. Risk factors involved in atrial fibrosis

The past few years have witnessed an impressive growth in the number of studies studying the signalling pathways involved in atrial fibrosis, but the specific mechanism remains poorly understood. However, some effective therapeutic options that

Figure 1. Mechanism by which atrial fibrosis causes atrial fibrillation and the methods for diagnosis and treatment of atrial fibrosis.

target atrial fibrosis could not have been developed without taking into account the complex signalling pathways. The key factors and mechanisms leading to progressive atrial fibrosis are discussed below (Fig. 3).

TGF-β_1. TGF-β is one of the most potent pro-fibrotic growth factors, with >30 family members, including TGF-β_{1-3}, of which TGF-β_1 is the predominant member (41). TGF-β_1 promotes the synthesis of collagen fibres by cardiac fibroblasts and their differentiation into myofibroblasts via the typical Smad-dependent and non-canonical Smad-independent pathways (42). In the canonical Smad-dependent pathway, TGF-β binds to two types of serine/threonine kinase receptors [type I TGFβ receptor (TβRI)/activin receptor-like kinase 5 and TβRII], which together form a Smad2/3/4 complex that subsequently leads to Smad protein-mediated signal transduction (43,44). Smad7, an inhibitory Smad, antagonizes the TGF-β/Smad signalling pathway (44). Non-canonical pathways include the mitogen-activated protein kinases (MAPKs)/TGF-β_1/tumour necrosis factor (TNF) receptor associated factor 6/TGF-β-activated kinase 1, TGF-β_1/cluster of differentiation (CD)44/signal transducer and activator of transcription 3 (STAT3) and angiotensin II (Ang II)/TGF-β/Ras homolog family member A (RhoA)/Rho-kinase (ROCK) signalling pathways (45-47). The thrombospondin-1/TGF-β/MMP-9 axis is also involved in atrial fibrosis in patients with AF (48).

Atrial myofibril loss was higher in patients with AF compared with those with sinus rhythm. In an electrical stimulation experiment of cultured HL-1 atrial myocytes, Yeh *et al* (49) demonstrated that Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-mediated oxidative stress may account for tachycardia-induced myofibril degradation. They also reported increased levels of p-Smad3 in a tachypacing model, and confirmed there was crosstalk between the two signalling pathways in tachypacing-stimulated reactive oxygen species (ROS) production.

Renin-Ang-aldosterone system (RAAS). The RAAS is a system involving the pathophysiological involvement of multiple organs including the heart, kidney and lungs (50). Ang II is a major mediator of this system and serves an important role in atrial fibrosis. Ang II exerts pro-fibrotic effects by binding to its type 1 receptor (AT$_1$-R), a member of the G-protein-coupled receptor superfamily. G protein activation stimulates phospholipase C (PLC) to generate inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 mediates the increase of Ca^{2+} levels in the cytoplasm. Intracellular Ca^{2+} overload promotes fibroblast proliferation and differentiation (51). DAG activates protein kinase C, which in turn activates extracellular-signal-regulated kinases (ERKs). In addition, acting as a potent NADPH oxidase activator, Ang II induces ROS overproduction, which, in-turn, activates multiple downstream second messengers, including MAPK, nuclear factor-κB and cytokines (52,53). Through the activation of the MAPK signalling pathway, Ang II promotes the secretion of TGF-β_1. TGF-β_1 reciprocally upregulates the density of AT$_1$-R and the expression of connective tissue growth factor (CTGF), thereby further promoting fibrosis (54). Conversely, the stimulation of Ang II type 2 receptor (AT$_2$-R) constrains the pro-fibrotic effects of AT$_1$-R (55). Several studies have confirmed that the blockade of Ang II by Ang-converting enzyme inhibitors (ACEIs) or Ang receptor blockers (ARBs) reduces atrial fibrosis (56,57). Aldosterone is the end product of RAAS, and its role in AF pathophysiology has proven very valuable. By binding to the mineralocorticoid receptor (MR), aldosterone serves its pro-fibrotic roles via the MAPK intracellular signalling pathway in HL-1 atrial myocytes (58,59). Furthermore, there is crosstalk between the MR/AT$_1$-R and MAPK signalling pathway, suggesting that the combined blocking of MR and AT$_1$-R can prevent the occurrence of AF (59).

Inflammation. A previous study suggested that inflammation is closely associated with AF (60). This association was first noticed due to the high incidence of postoperative AF (60). Bruins *et al* (60) first reported an association between C-reactive protein and arrhythmia in patients who suffered from coronary artery disease. Inflammatory cell infiltration and an increased serum level of inflammatory mediators, such as IL-1β, IL-6, IL-8, IL-10 and TNF-α were found to be associated with AF. Not only do the expression levels of these inflammatory mediators increase as the duration of AF increases, but some of these mediators can even be used to predict postoperative AF recurrence (61).

The pro-fibrotic effect of inflammation is generally attributed to oxidative stress, which promotes the initiation and perpetuation of AF by activating the MAPK signalling pathway (62). Mitochondria and NADPH oxidase are hypothesized to be the major sources of ROS, which is a second messenger that activates downstream signals. Amongst other things, uncoupled nitric oxide (NO) synthase and xanthine oxidase are also sources of ROS (63). Ang II promotes ROS production, and both are involved in aberrant Ca^{2+} handling, increasing the cytosolic Ca^{2+} concentration (64,65). Intracellular Ca^{2+} overload further aggravates electrical remodelling by downregulating the L-type Ca^{2+}-current (66). In addition, microRNA (miRNA/miR)-26 is also downregulated by the activation of the Ca^{2+}-calcineurin-nuclear factor of activated T-cells signalling pathway, promoting the expression of KCNJ2/I_{K1} in both cardiomyocytes and fibroblasts. Treatments targeting the upstream inflammatory cascade can decrease the inflammatory response and oxidative stress, and

Figure 2. Occurrence and perpetuation of atrial fibrillation and the origins of cardiac fibroblasts.

alleviate atrial structural and electrical remodelling, which further elucidates the mechanisms underlying this disease (67).

Adipose, particularly epicardial adipose tissue (EAT), is strongly associated with the initiation, duration and recurrence of AF. With regard to the pathological mechanism of EAT by which it promotes the occurrence and development of atrial fibrosis, considerable evidence has consistently confirmed its role in local inflammation. Abe *et al* (68,69) evaluated the levels of cytokines/chemokines in a specimen from human left atrial appendage. The results showed that the expression levels of IL-1, IL-6, IL-10 and TNF-α in EAT increased, consistent with a previous result from Mazurek *et al* (68,69). In addition, adipokines secreted by EAT are another mechanism underlying fibrosis. Activin A, an adipokine belonging to the TGF-β superfamily, has the ability to initiate atrial fibrosis (70). In addition, CTGF, a fibrotic cytokine that functions via the TGF-$β_1$/Smad pathway, has been shown to be upregulated in EAT and is strongly associated with AF (71,72).

Platelet-derived growth factor (PDGF). *PDGF* is a member of the PDGF/vascular endothelial growth factor family, which includes four isoforms, namely, PDGF-A, PDGF-B, PDGF-C and PDGF-D. PDGF serves a role in promoting fibroblast proliferation and differentiation via the MAPK, Janus kinase (JAK)/STAT, Ras/ERK kinase 1/2 and PLC pathways that are shared by both TGF-$β_1$ and Ang II. Mast cell infiltration and over-synthesis of PDGF-A were observed in mice atria affected by cardiac pressure overload, and atrial fibrosis and suscepti- bility to AF were increased in these mice. A PDGF-A-targeting antibody, as well as mast cell stabilizer or genetic mast cell depletion can attenuate these changes (73). Chen *et al* (74) evaluated the potential role of the PDGF-JAK-STAT pathway in LA-remodelling using a ventricular tachypacing-induced canine congestive heart failure (CHF) model. It was observed that the overexpression of PDGF-A, -C and -D in LA fibro- blasts of HF canine enhanced JAK-STAT expression and ECM secretion. Furthermore, the high levels of these PDGF isoforms substantially upregulated the mRNA expression levels of TGF$β_1$, which, in turn, advanced cardiac fibrosis (75).

MiRNAs. *In vivo* and *in vitro* studies have suggested that miRNAs may also serve a role in atrial fibrosis and AF. In addition to being involved in electrical remodelling, miRNAs also play important roles in atrial structural remodel- ling. Li *et al* (76) showed that miR-10a could inhibit the TGF-$β_1$/Smad signalling pathway to decrease the synthesis of

Figure 3. Signalling pathways associated with atrial fibrosis.

collagen, suppress the proliferation of cardiac fibroblasts and ameliorate cardiac fibrosis. Studies have shown that miR-21 can target sprouty homolog 1, an ERK inhibitor, which activates the ERK/MAPK signalling pathway to promote cardiac fibroblast proliferation and fibrogenesis (77,78). A previous study by He et al (79) demonstrated that Smad7 is also a target of miR-21. They used rapid atrial pacing in rats to induce atrial fibrosis and AF. The results showed a higher expression level of miR-21 and lower levels of Smad-7, blunting the inhibitory effect of Smad7 on the TGF-β/Smad-2/3 signalling pathway (79). In a study by Wang et al (80) miR-27b was found to inactivate the Smad2/3 pathway, reducing the incidence and duration of AF, as well as attenuating atrial fibrosis, which was evidenced by the reduced expression levels of smooth muscle α-actin, collagen-I and collagen III (80). miR-30 and miR-133 target TGF-β and TGF-β receptor to affect collagen synthesis (81). They can also negatively regulate cardiac fibrosis by inhibiting the expression of CTGF.

4. Ventricular fibrosis in AF

Significant non-invasive technological advances have opened up more possibilities for the characterization and quantification of focal and diffuse left ventricular (LV) myocardial fibrosis in patients with AF, which have provided evidence that the cardiac pro-fibrotic microenvironment in AF is unlikely to be strictly limited to the atria (82,83). Late gadolinium enhanced cardiac magnetic resonance (LGE-CMR) imaging is an established technique for the evaluation of focal myocardial scars on the basis of the different abilities of healthy myocardium and areas of fibrotic tissue to clear gadolinium (84). With regard to diffuse myocardial fibrosis, gadolinium contrast may be evenly retained throughout the diffusely fibrotic myocardium, and the signal intensity of diffusely fibrotic areas may be nearly isointense, as compared with that of normal tissue. Diffuse interstitial fibrosis is challenging to distinguish using conventional delayed enhancement (DE)-CMR (85-87). With the development of novel contrast-enhanced T_1 mapping techniques, diffuse myocardial fibrosis may be detected through a quantitative measure of the myocardial T_1 relaxation times (86,87). Ling et al (88) used myocardial T_1 mapping in patients with AF to detect diffuse myocardial fibrosis of the LV. They showed that LV fibrosis could be detected and quantified by T_1 mapping in patients with AF and HF concurrently. Of note, several studies have shown that diffuse ventricular fibrosis measured by T1 mapping on CMR predicts the success of catheter ablation for AF, although the mechanism behind this association is not clear (89,90).

There may be some possible explanations for the association between AF and the presence of diffuse LV fibrosis. For example, arrhythmia-mediated cardiomyopathy may predispose patients to diffuse interstitial fibrosis (91). Ventricular fibrotic changes are more extensive in patients with AF compared to those with sinus rhythm (82,92). Data from an animal study suggested that a rapid ventricular response from AF could result in a decrease in ventricular function, and an

increase in ventricular and atrial fibrosis (93). In addition, the restoration of the sinus rhythm with catheter ablation is accompanied by significant improvements in reverse cardiac remodelling and ventricular function (94). Fibrotic cardiomyopathy has been suggested to predispose patients to diffuse interstitial fibrosis development. A plethora of non-cardiac factors have been shown to contribute to fibrosis in AF, including obesity, systemic inflammation, metabolic syndrome, thyrotoxicosis and obstructive sleep apnoea, which could ultimately affect the myocardium (95). Obstructive and central sleep apnoea leads to myocardial hypertrophy and diastolic dysfunction, thus further potentiating the development of HF in patients with AF (96,97). Obesity in AF is associated with diastolic ventricular impairment and myocardial lipidosis (98). Alternatively, the association between AF and ventricular fibrosis may also be due to other factors which have yet to be uncovered (99). In summary, ventricular fibrosis in response to AF may be regulated by multiple mechanisms. Additional studies focusing on the association between AF and diffuse myocardial fibrosis are required.

Several common mechanisms are known to contribute to atrial and ventricular fibrosis in AF, whereas the extent of fibrosis may vary between the 2 parts of the heart. Transgenic mice with TGF-β_1 exhibited higher TGF-β_1 levels in the atria than in the ventricles under the control of an α-MHC promoter (100). In this model, 80 pro-fibrotic genes in the atria were overexpressed and only 2 genes in the ventricle were differentially expressed, as shown by RNA microarray analysis (100). Similarly, transgenic mice overexpressing ACE exhibited a hypertrophic and dilated atria with focal atrial fibrosis, but normal ventricles (101). This differential chamber-specific fibrotic response to ACE overexpression could be partly explained by the differential AT$_1$ receptor expression in the atria and ventricles (102). It has been shown that atrial fibroblasts show greater fibrotic and oxidative responses to TGF-β_1 than ventricular fibroblasts (103), indicating that the atria has a more potent fibrotic response to various stimuli (20). The results of these studies suggested that the mechanisms involved in the development of atrial and ventricular fibrosis are different. Further studies are required to investigate whether other important signalling pathways contribute to the development of selective fibrosis in the atria, compared to the ventricles.

5. Atrial fibrosis and stroke risk in AF

There is increasing evidence of an association between atrial fibrosis and the risk of stroke in patients with AF. Daccaret *et al* (104) identified an association between the percentage of atrial fibrosis detected on LGE-CMR and a higher CHADS$_2$-score [CHF, hypertension, age >75 years, diabetes mellitus and stroke or transient ischemic attack (TIA)], and a history for stroke. Left atrium fibrosis is a strong predictor of left atrial thrombosis or cerebrovascular events, particularly stroke or TIA (105,106). Another study by Disertori *et al* (107) showed that the risk of stroke may be independently associated with structural fibrotic remodelling. Left atrial fibrosis is also associated with an increased risk of cryptogenic stroke (108). Even in patients

without AF, embolic stroke of an undetermined source has been found to be correlated to atrial fibrosis (109). Spronk *et al* showed that hypercoagulability in itself may stimulate fibroblasts and increase fibrosis. It was revealed that anticoagulation therapy may prevent thromboembolic events, partly through influencing the substrate by reducing the degree of fibrosis (110). In combination, these studies provided quantitative evidence that the risk of stroke in patients with AF may be associated with the severity of the LA fibrosis. However, there is a paucity of data on the pathophysiological link and molecular mechanisms between atrial fibrosis and thromboembolism. Atrial fibrosis, one of several markers of an AF-prone atrial substrate, promotes the re-entry of electrical current by increasing heterogeneity of conduction in the atria, which ultimately impairs atrial contractility, and reduces ejection fraction and flow velocity (111). It thus causes increased platelet aggregation, which further enhances the milieu of intra-atrial stasis (111). Endothelium/endocardial tissue not only forms a barrier between platelets and extracellular matrix, but also secretes factors such as NO and heparan sulphates to prevent the activation of the coagulation cascade. Endothelial dysfunction develops as a result of atrial fibrosis in patients with AF and promotes thrombus formation (112).

Inflammation and oxidative stress are known to serve an important pathogenic role in AF, leading to cardiac fibrosis (113,114). Inflammatory markers, such as TGF-β_1, IL-6 and TNF-α, have been detected in patients with AF and have been shown to affect the functional stability of myocytes and endothelial cells, as well as promote atrial fibrosis (53,115). Inflammatory marker levels were associated with a risk of stroke in patients with chronic AF during follow-up (116,117). There may be a close interplay amongst atrial fibrosis, inflammation and oxidative stress, which, in turn, leads to endothelial and/or endocardial dysfunction and a pro-thrombotic state; however, further studies are required to advance from theoretical to pragmatic outcomes.

Stroke in AF appears to be a complex and poorly understood phenomenon, and the means by which LA fibrosis predisposes patients to thrombus formation is not completely clear. LA fibrosis represents a marker of disease, which can improve the prediction of thromboembolic events in patients with AF.

6. Treatment approaches targeting atrial fibrosis

Conventional antiarrhythmic agent approaches have limited efficacy and have several adverse effects. Increased attention has therefore been diverted to upstream therapies with the use of non-antiarrhythmic drugs targeting substrate development and modifying risk factors for human AF. Specifically, one of the most relevant objectives of upstream therapy is the control of the development and progression of atrial fibrosis, which is a hallmark of structural remodelling in AF and is considered a substrate for perpetuation of AF (118-120). It has become clear that Ang II is a potent stimulator of pro-fibrotic pathways during AF, and the inhibition of the RAAS by ACEIs, ARBs and mineralocorticoid receptor antagonists (MRAs) was shown to reduce the progression of fibrosis (121). Several ACEIs have been shown to effectively suppress atrial fibrosis

Figure 4. Tailored treatment for atrial fibrosis. HF, heart failure; HTN, hypertension; DE-CMR, delayed-enhancement cardiovascular magnetic resonance; EAVM, electroanatomic voltage mapping; RFCA, radiofrequency catheter ablation.

and prevent the development of the AF substrate (122,123). The potential of AT_1 receptor blockers for the treatment of fibrosis and AF has been previously explored. In spontaneously hypertensive rats, valsartan reduced the degree of myocardial fibrosis (124). Similarly, losartan and candesartan have been previously shown to suppress atrial remodelling by inhibiting left atrial fibrosis and improving AF indices in experimental models (125,126). MRAs also appear to be potential agents for fibrosis. Lavall *et al* (58) found that mineralocorticoid receptor blockers could effectively reduce the incidence of new-onset AF in patients with systolic heart failure. Eplerenone treatment has been shown to inhibit the development of atrial hypertrophy and fibrosis compared with the control group animals (127). Retrospective analyses and meta-analyses of databases from clinical trials have suggested a role of inhibitors of the Ang axis in AF prevention, particularly in patients with LV hypertrophy and systolic LV dysfunction (128-132). However, other clinical studies reported no beneficial effects of Ang blockade treatment on the incidence of recurrent AF (133,134). These conflicting outcomes may be partly attributed to the possible interactions or synergistic effects with other drugs including ACEIs, amiodarone and β-blockers, and the differences in the baseline parameters of patients, such as ventricular function, structural substrates and influence of fibrosis-causing factors. The beneficial effects of upstream therapies may be due to the prevention of structural remodelling in both the left atrium and the LV, improved LV haemodynamics and reduced atrial stretch, and direct or indirect modulation of ion-channel function and other unknown factors.

There is less evidence in favour of therapies, such as polyunsaturated omega-3 fatty acids or the inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase (statins) in the inhibition of fibrosis and atrial structural remodelling. Simvastatin attenuated CHF-induced atrial structural remodelling and AF promotion (135). Similarly, statin therapy may contribute to the prevention of AF in the postoperative period of cardiac surgery (136). Omega-3 poly-unsaturated fatty acids have been found to suppress

AF in patients with an evident structural substrate and presence of atrial remodelling, combined with high levels of circulating inflammatory biomarkers (137). Treatment of CHF canines with the antifibrotic drug pirfenidone resulted in significantly reduced TGF-β_1 levels, arrhythmogenic atrial remodelling and AF vulnerability (138). In conclusion, these results further highlight the value of upstream AF prevention therapy.

The potential mechanisms underlying the positive effects of atrial fibrosis treatment and any fibrosis-related AF in humans is not well understood. A deeper understanding of these fundamental mechanisms may assist in identifying novel targets for pharmacological interventions, which may be even more effective than conventional antiarrhythmic therapy.

Percutaneous catheter ablation is a widely used and effective clinical treatment for rhythm control in patients with AF (139). Circumferential pulmonary vein isolation (CPVI) alone is an ablation strategy that is effective in the majority of patients with paroxysmal AF. However, the frequent need for re-ablation coupled with the lower long-term success rates are still major limitations of catheter ablation procedures in the treatment of non-paroxysmal AF (140). AF evolves from a singular rhythm disturbance to the complex condition that is cardiomyopathy through arrhythmia substrates (141,142). Studies have reported the detection of atrial fibrosis using DE-MR imaging (MRI) and electroanatomic voltage mapping (EAVM) (104,143-146), and suggested that it is an important predictor of the outcome of AF interventions (146-148).

Substrate modification targeting fibrotic tissue has been performed for several years using EAVM (149); this procedure has been described in more detail previously (149). Kottkamp *et al* (150) described a patient-tailored ablation strategy termed 'box isolation of fibrotic areas', which involves the circumferential isolation of substantially affected fibrotic areas (<0.5 mV), providing a novel selection criterion for PVI-only ablation in patients with non-paroxysmal AF. Rolf *et al* (144) also demonstrated a tailored substrate modification based on voltage criteria. Yamaguchi *et al* (151) described an approach of homogenizing areas of substantial

fibrosis; briefly, the ablation of all detectable electrograms within the target areas was defined as an area with bipolar electrograms of <0.5 mV and, in addition, short linear lesions were created so as to ablate potential conduction channels. During a follow-up in their study, absence of AF was notably higher in the low-voltage zone-based substrate modification group compared with the group that only underwent PVI (38% vs. 72%). A total of 144/201 patients (74%) who underwent LA low voltage area-guided AF substrate modification as an adjunct to PVI during a median follow-up of 3.1 years were free from recurrence (152). Similarly, Jadidi *et al* (153) previously reported that absence of arrhythmia was higher in the substrate modification approach group compared with the matched control group that only received PVI (69% vs. 47%). As compared with the stepwise approach for the treatment of non-paroxysmal AF, a strategy of selective electrophysiologically guided atrial substrate modification after CPVI and cavotricuspid isthmus ablation was found to be more clinically effective (154). Voltage mapping as a tool for describing fibrotic changes remains under investigation and still requires standardization. For example, the measured voltage depends on the rhythm, various thresholds of voltage amplitude used to define fibrotic areas, the contact of the electrode to the tissue, the electrode size and spacing, the thickness of the atrial myocardium and other variables (155).

LGE-CMR provides a non-invasive tool for detecting, quantifying and localizing atrial fibrosis. Jadidi *et al* (156) demonstrated that the large fibrotic substrate detected with LGE-CMR is associated with the complex fractionated atrial electrogram, proposed as a relevant phenomenon maintaining AF. Recent data have reported patients being free of AF recurrence after catheter ablation led to a significant attenuation of the LA fibrosis burden, as shown by follow-up CMR studies (157). In contrast to invasive EAVM during the ablation procedure, LGE-CMR-guided fibrosis management has improved our understanding of the individual underlying arrhythmia substrate during the natural course of human AF. Fochler *et al* (158) reported that an LGE-MRI anatomically guided approach for the treatment of recurrent arrhythmias post-AF ablation is feasible and effective. Similarly, another study highlights the potential use of the optimal set of patient-specific targets to ablate fibrotic atrial substrates (159). The LGE-CMR-guided assessment may provide novel insights into patient-specific AF stages and treatment strategies; however, this modality requires extensive MRI experience, and its reproducibility is still under intensive investigation (160).

At present, the success rate of non-individualized substrate modifications of catheter ablation procedures for patients with persistent and/or long-standing AF is disappointingly low (161). Completely novel catheter ablation strategies that are based on the individual substrates rather than on the 'phenotype' in paroxysmal vs. non-paroxysmal AF are thus required. The knowledge of the individual amount and distribution pattern of a patient's AF fibrotic LA substrate allows for a personalized path to prevention, monitoring or even targeting arrhythmia substrates in patients with AF, which need to be confirmed and validated with respect to efficacy, as well as safety in prospective multicentre randomized studies.

7. Conclusion and future perspectives

The prevalence and health burden of AF worldwide highlights the importance of the development of high-accuracy and precision therapies aimed at preventing or reversing AF. Clinical and experimental studies have reported that atrial fibrosis is closely associated with the occurrence and maintenance of AF. The development of fibrosis is a highly complex, multifactorial and patient-specific process, involved in complex neurohumoral, cellular and molecular interactions. Although a significant understanding has already been obtained that has led to the identification of novel targets for fibrotic mechanism-based therapies, the precise role of fibrosis in AF initiation and maintenance remains to be determined. There is a wide variation in the presence, extent and pattern of LA fibrosis. Its use for AF treatment may assist in designing individually tailored ablation approached for determining the ablation strategy following pulmonary vein isolation and highlights the need for repeated ablation procedures, which could potentially significantly improve our understanding of AF and ablation outcomes.

An improved understanding of the roles, characteristics and mechanisms of fibrosis during AF may facilitate the identification of new clinical biomarkers, as well as assist in the development of novel, more effective and patient-tailored treatment approaches for AF by targeting the fibrotic substrate (Fig. 4).

Acknowledgements

Not applicable.

Funding

Availability of data and material

Not applicable.

Authors' contributions

CYL, JRZ, WNH and SNL wrote the manuscript. SNL critically reviewed the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Sanoski CA: Clinical, economic, and quality of life impact of atrial fibrillation. J Manag Care Pharm 15 (6 Suppl B): S4-S9, 2009.
2. Chen PS, Chen LS, Fishbein MC, Lin SF and Nattel S: Role of the autonomic nervous system in atrial fibrillation: Pathophysiology and therapy. Circ Res 114: 1500-1515, 2014.
3. Denham NC, Pearman CM, Caldwell JL, Madders GWP, Eisner DA, Trafford AW and Dibb KM: Calcium in the pathophysiology of atrial fibrillation and heart failure. Front Physiol 9: 1380, 2018.
4. Pellman J and Sheikh F: Atrial fibrillation: Mechanisms, therapeutics, and future directions. Compr Physiol 5: 649-665, 2015.
5. Polyakova V, Miyagawa S, Szalay Z, Risteli J and Kostin S: Atrial extracellular matrix remodelling in patients with atrial fibrillation. J Cell Mol Med 12: 189-208, 2008.
6. Nattel S: Molecular and cellular mechanisms of atrial fibrosis in atrial fibrillation. JACC Clin Electrophysiol 3: 425-435, 2017.
7. de Boer RA, De Keulenaer G, Bauersachs J, Brutsaert D, Cleland JG, Diez J, Du XJ, Ford P, Heinzel FR, Lipson KE, et al: Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the committee of translational research of the heart failure association (HFA) of the European society of cardiology. Eur J Heart Fail 21: 272-285, 2019.
8. Kong P, Christia P and Frangogiannis NG: The pathogenesis of cardiac fibrosis. Cell Mol Life Sc 71: 549-574, 2014.
9. Fan D, Takawale A, Lee J and Kassiri Z: Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair 5: 15, 2012.
10. Rog-Zielinska EA, Norris RA, Kohl P and Markwald R: The living scar-cardiac fibroblasts and the injured heart. Trends Mol Med 22: 99-114, 2016.
11. Kohl P and Gourdie RG: Fibroblast-myocyte electrotonic coupling: Does it occur in native cardiac tissue? J Mol Cell Cardiol 70: 37-46, 2014.
12. Ongstad E and Kohl P: Fibroblast-myocyte coupling in the heart: Potential relevance for therapeutic interventions. J Mol Cell Cardiol 91: 238-246, 2016.
13. Nguyen TP, Qu Z and Weiss JN: Cardiac fibrosis and arrhythmogenesis: The road to repair is paved with perils. J Mol Cell Cardiol 70: 83-91, 2014.
14. Krul SPJ, Berger WR, Smit NW, van Amersfoorth SC, Driessen AH, van Boven WJ, Fiolet JW, van Ginneken AC, van der Wal AC, de Bakker JM, et al: Atrial fibrosis and conduction slowing in the left atrial appendage of patients undergoing thoracoscopic surgical pulmonary vein isolation for atrial fibrillation. Circ Arrhythm Electrophysiol 8: 288-295, 2015.
15. Nattel S: Electrical coupling between cardiomyocytes and fibroblasts: Experimental testing of a challenging and important concept. Cardiovasc Res 114: 349-352, 2018.
16. Perbellini F, Watson SA, Bardi I and Terracciano CM: Heterocellularity and cellular cross-talk in the cardiovascular system. Front Cardiovasc Med 5: 143, 2018.
17. Pinto AR, Ilinykh A, Ivey MJ, Kuwabara JT, D'Antoni ML, Debuque R, Chandran A, Wang L, Arora K, Rosenthal NA and Tallquist MD: Revisiting cardiac cellular composition. Circ Res 118: 400-409, 2016.
18. Zhou P and Pu WT: Recounting cardiac cellular composition. Circ Res 118: 368-370, 2016.
19. Ma Y, de Castro Brás LE, Toba H, Iyer RP, Hall ME, Winniford MD, Lange RA, Tyagi SC and Lindsey ML: Myofibroblasts and the extracellular matrix network in post-myocardial infarction cardiac remodeling. Pflugers Arch 466: 1113-127, 2014.
20. Burstein B, Libby E, Calderone A and Nattel S: Differential behaviors of atrial versus ventricular fibroblasts: A potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. Circulation 117: 1630-1641, 2008.
21. Moore-Morris T, Cattaneo P, Puceat M and Evans SM: Origins of cardiac fibroblasts. J Mol Cell Cardiol 91: 1-5, 2016.
22. Krenning G, Zeisberg EM and Kalluri R: The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol 225: 631-637, 2010.
23. Moore-Morris T, Guimarães-Camboa N, Banerjee I, Zambon AC, Kisseleva T, Velayoudon A, Stallcup WB, Gu Y, Dalton ND, Cedenilla M, et al: Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. J Clin Invest 124: 2921-2934, 2014.
24. Ali SR, Ranjbarvaziri S, Talkhabi M, Zhao P, Subat A, Hojjat A, Kamran P, Müller AM, Volz KS, Tang Z, et al: Developmental heterogeneity of cardiac fibroblasts does not predict pathological proliferation and activation. Circ Res 115: 625-635, 2014.

25. Lajiness JD and Conway SJ: The dynamic role of cardiac fibroblasts in development and disease. J Cardiovasc Transl Res 5: 739-748, 2012.
26. Travers JG, Kamal FA, Robbins J, Yutzey KE and Blaxall BC: Cardiac fibrosis: The fibroblast awakens. Circ Res 118: 1021-1040, 2016.
27. Kim SK, Park JH, Kim JY, Choi JI, Joung B, Lee MH, Kim SS, Kim YH and Pak HN: High plasma concentrations of transforming growth factor-β and tissue inhibitor of metalloproteinase-1: Potential non-invasive predictors for electroanatomical remodeling of atrium in patients with non-valvular atrial fibrillation. Circ J 75: 557-564, 2011.
28. Goudis CA, Kallergis EM and Vardas PE: Extracellular matrix alterations in the atria: Insights into the mechanisms and perpetuation of atrial fibrillation. Europace 14: 623-630, 2012.
29. Frangogiannis NG: The extracellular matrix in myocardial injury, repair, and remodeling. J Clin Invest 127: 1600-1612, 2017.
30. Rienks M, Papageorgiou AP, Frangogiannis NG and Heymans S: Myocardial extracellular matrix: An ever-changing and diverse entity. Circ Res 114: 872-888, 2014.
31. Liu X, Meng L, Shi Q, Liu S, Cui C, Hu S and Wei Y: Dermatopontin promotes adhesion, spreading and migration of cardiac fibroblasts in vitro. Matrix Biol 32: 23-31, 2013.
32. López B, González A, Ravassa S, Beaumont J, Moreno MU, San José G, Querejeta R and Díez J: Circulating biomarkers of myocardial fibrosis: The need for a reappraisal. J Am Coll Cardiol 65: 2449-2456, 2015.
33. Richter B, Gwechenberger M, Socas A, Zorn G, Albinni S, Marx M, Wolf F, Bergler-Klein J, Loewe C, Bieglmayer C, et al: Time course of markers of tissue repair after ablation of atrial fibrillation and their relation to left atrial structural changes and clinical ablation outcome. Int J Cardiol 152: 231-236, 2011.
34. Kawamura M, Munetsugu Y, Kawasaki S, Onishi K, Onuma Y, Kikuchi M, Tanno K and Kobayashi Y: Type III procollagen-N-peptide as a predictor of persistent atrial fibrillation recurrence after cardioversion. Europace 14: 1719-1725, 2012.
35. Spinale FG: Myocardial matrix remodeling and the matrix metalloproteinases: Influence on cardiac form and function. Physiol Rev 87: 1285-1342, 2007.
36. Li M, Yang G, Xie B, Babu K and Huang C: Changes in matrix metalloproteinase-9 levels during progression of atrial fibrillation. J Int Med Res 42: 224-230, 2014.
37. Nakano Y, Niida S, Dote K, Takenaka S, Hirao H, Miura F, Ishida M, Shingu T, Sueda T, Yoshizumi M and Chayama K: Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol 43: 818-825, 2004.
38. Wu G, Wang S, Cheng M, Peng B, Liang J, Huang H, Jiang X, Zhang L, Yang B, Cha Y, et al: The serum matrix metalloproteinase-9 level is an independent predictor of recurrence after ablation of persistent atrial fibrillation. Clinics (Sao Paulo) 71: 251-256, 2016.
39. Liu Y, Xu B, Wu N, Xiang Y, Wu L, Zhang M, Wang J, Chen X, Li Y and Zhong L: Association of MMPs and TIMPs with the occurrence of atrial fibrillation: A systematic review and meta-analysis. Can J Cardiol 32: 803-813, 2016.
40. Molvin J, Jujic A, Melander O, Pareek M, Råstam L, Lindblad U, Daka B, Leosdottir M, Nilsson P, Olsen M and Magnusson M: Exploration of pathophysiological pathways for incident atrial fibrillation using a multiplex proteomic chip. Open Heart 7: e001190, 2020.
41. Morikawa M, Derynck R and Miyazono K: TGF-β and the TGF-β family: Context-dependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol 8: a021873, 2016.
42. Biernacka A, Dobaczewski M and Frangogiannis NG: TGF-beta signaling in fibrosis. Growth Factors 29: 196-202, 2011.
43. Heldin CH, Miyazono K and ten Dijke P: TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390: 465-471, 1997.
44. Euler-Taimor G and Heger J: The complex pattern of SMAD signaling in the cardiovascular system. Cardiovasc Res 69: 15-25, 2006.
45. Zhang D, Chen X, Wang Q, Wu S, Zheng Y and Liu X: Role of the MAPKs/TGF-β1/TRAF6 signaling pathway in postoperative atrial fibrillation. PLoS One 12: e0173759, 2017.
46. Chang SH, Yeh YH, Lee JL, Hsu YJ, Kuo CT and Chen WJ: Transforming growth factor-β-mediated CD44/STAT3 signaling contributes to the development of atrial fibrosis and fibrillation. Basic Res Cardiol 112: 58, 2017.

47. Liu LJ, Yao FJ, Lu GH, Xu CG, Xu Z, Tang K, Cheng YJ, Gao XR and Wu SH: The role of the Rho/ROCK pathway in Ang II and TGF-β1-induced atrial remodeling. PLoS One 11: e0161625, 2016.

48. Yang Z and Wang H: Increased expression of the TSP-1/TGF-β/MMP-9 axis in atrial fibrillation related to rheumatic heart disease. Int J Clin Exp Med 11: 5699-5706, 2018.

49. Yeh YH, Kuo CT, Chan TH, Chang GJ, Qi XY, Tsai F, Nattel S and Chen WJ: Transforming growth factor-β and oxidative stress mediate tachycardia-induced cellular remodelling in cultured atrial-derived myocytes. Cardiovasc Res 91: 62-70, 2011.

50. Patel S, Rauf A, Khan H and Abu-Izneid T: Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. Biomed Pharmacother 94: 317-325, 2017.

51. Harada M, Luo X, Qi XY, Tadevosyan A, Maguy A, Ordog B, Ledoux J, Kato T, Naud P, Voigt N, *et al*: Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation. Circulation 126: 2051-2064, 2012.

52. Liu J, Geng J, Zhao H, Yun F, Wang X, Yan S, Ding X, Li W, Wang D, Li J, *et al*: Valsartan reduced atrial fibrillation susceptibility by inhibiting atrial parasympathetic remodeling through MAPKs/neurturin pathway. Cell Physiol Biochem 36: 2039-2050, 2015.

53. Harada M, Van Wagoner DR and Nattel S: Role of inflammation in atrial fibrillation pathophysiology and management. Circ J 79: 495-502, 2015.

54. Gu J, Liu X, Wang QX, Tan HW, Guo M, Jiang WF and Zhou L: Angiotensin II increases CTGF expression via MAPKs/TGF-β1/TRAF6 pathway in atrial fibroblasts. Exp Cell Res 318: 2105-2115, 2012.

55. Nouet S and Nahmias C: Signal transduction from the angiotensin II AT2 receptor. Trends Endocrinol Metab 11: 1-6, 2000.

56. Sakabe M, Fujiki A, Nishida K, Sugao M, Nagasawa H, Tsuneda T, Mizumaki K and Inoue H: Enalapril prevents perpetuation of atrial fibrillation by suppressing atrial fibrosis and over-expression of connexin43 in a canine model of atrial pacing-induced left ventricular dysfunction. J Cardiovasc Pharmacol 43: 851-859, 2004.

57. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z and Nattel S: Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104: 2608-2614, 2001.

58. Lavall D, Selzer C, Schuster P, Lenski M, Adam O, Schäfers HJ, Böhm M and Laufs U: The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J Biol Chem 289: 6656-6668, 2014.

59. Tsai CF, Yang SF, Chu HJ and Ueng KC: Cross-talk between mineralocorticoid receptor/angiotensin II type 1 receptor and mitogen-activated protein kinase pathways underlies aldosterone-induced atrial fibrotic responses in HL-1 cardiomyocytes. Int J Cardiol 169: 17-28, 2013.

60. Bruins P, te Velthuis H, Yazdanbakhsh AP, Jansen PG, van Hardevelt FW, de Beaumont EM, Wildevuur CR, Eijsman L, Trouwborst A and Hack CE: Activation of the complement system during and after cardiopulmonary bypass surgery: Postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 96: 3542-3548, 1997.

61. Hu YF, Chen YJ, Lin YJ and Chen SA: Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol 12: 230-243, 2015.

62. Huang CX, Liu Y, Xia WF, Tang YH and Huang H: Oxidative stress: A possible pathogenesis of atrial fibrillation. Med Hypotheses 72: 466-467, 2009.

63. Sovari AA and Dudley SC Jr: Reactive oxygen species-targeted therapeutic interventions for atrial fibrillation. Front Physiol 3: 311, 2012.

64. Görlach A, Bertram K, Hudecova S and Krizanova O: Calcium and ROS: A mutual interplay. Redox Biol 6: 260-271, 2015.

65. Youn JY, Zhang J, Zhang Y, Chen H, Liu D, Ping P, Weiss JN and Cai H: Oxidative stress in atrial fibrillation: An emerging role of NADPH oxidase. J Mol Cell Cardiol 62: 72-79, 2013.

66. Nattel S and Harada M: Atrial remodeling and atrial fibrillation: Recent advances and translational perspectives. J Am Coll Cardiol 63: 2335-2345, 2014.

67. Sirish P, Li N, Timofeyev V, Zhang XD, Wang L, Yang J, Lee KS, Bettaieb A, Ma SM, Lee JH, *et al*: Molecular mechanisms and new treatment paradigm for atrial fibrillation. Circ Arrhythm Electrophysiol 9: e003721, 2016.

68. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O'Brien S, Keiper EA, Johnson AG, *et al*: Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 108: 2460-2466, 2003.

69. Abe I, Teshima Y, Kondo H, Kaku H, Kira Y, Ikebe Y, Saito S, Fukui A, Shinohara T, Yufu K, *et al*: Association of fibrotic remodeling and cytokines/chemokines content in epicardial adipose tissue with atrial myocardial fibrosis in patients with atrial fibrillation. Heart Rhythm 15: 1717-1727, 2018.

70. Venteclef N, Guglielmi V, Balse E, Gaborit B, Cotillard A, Atassi F, Amour J, Leprince P, Dutour A, Clément K and Hatem SN: Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines. Eur Heart J 36: 795-805a, 2015.

71. Wang Q, Wang X, Yin L, Wang J, Shen H, Gao Y, Min J, Zhang Y and Wang Z: Human epicardial adipose tissue cTGF expression is an independent risk factor for atrial fibrillation and highly associated with atrial fibrosis. Sci Rep 8: 3585, 2018.

72. Li Y, Jian Z, Yang ZY, Chen L, Wang XF, Ma RY and Xiao YB: Increased expression of connective tissue growth factor and transforming growth factor-beta-1 in atrial myocardium of patients with chronic atrial fibrillation. Cardiology 124: 233-240, 2013.

73. Liao CH, Akazawa H, Tamagawa M, Ito K, Yasuda N, Kudo Y, Yamamoto R, Ozasa Y, Fujimoto M, Wang P *et al*: Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J Clin Invest 120: 242-253, 2010.

74. Chen Y, Surinkaew S, Naud P, Qi XY, Gillis MA, Shi YF, Tardif JC, Dobrev D and Nattel S: JAK-STAT signalling and the atrial fibrillation promoting fibrotic substrate. Cardiovasc Res 113: 310-320, 2017.

75. Tuuminen R, Nykänen AI, Krebs R, Soronen J, Pajusola K, Keränen MA, Koskinen PK, Alitalo K and Lemström KB: PDGF-A, -C, and -D but not PDGF-B increase TGF-beta1 and chronic rejection in rat cardiac allografts. Arterioscler Thromb Vasc Biol 29: 691-698, 2009.

76. Li PF, He RH, Shi SB, Li R, Wang QT, Rao GT and Yang B: Modulation of miR-10a-mediated TGF-β1/Smads signaling affects atrial fibrillation-induced cardiac fibrosis and cardiac fibroblast proliferation. Biosci Rep 39: BSR20181931, 2019.

77. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, *et al*: MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456: 980-984, 2008.

78. Adam O, Löhfelm B, Thum T, Gupta SK, Puhl SL, Schäfers HJ, Böhm M and Laufs U: Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol 107: 278, 2012.

79. He X, Zhang K, Gao X, Li L, Tan H, Chen J and Zhou Y: Rapid atrial pacing induces myocardial fibrosis by down-regulating Smad7 via microRNA-21 in rabbit. Heart Vessels 31: 1696-1708, 2016.

80. Wang Y, Cai H, Li H, Gao Z and Song K: Atrial overexpression of microRNA-27b attenuates angiotensin II-induced atrial fibrosis and fibrillation by targeting ALK5. Hum Cell 31: 251-260, 2018.

81. Chen Y, Wakili R, Xiao J, Wu CT, Luo X, Clauss S, Dawson K, Qi X, Naud P, Shi YF, *et al*: Detailed characterization of microRNA changes in a canine heart failure model: Relationship to arrhythmogenic structural remodeling. J Mol Cell Cardiol 77: 113-124, 2014.

82. Shantsila E, Shantsila A, Blann AD and Lip GY: Left ventricular fibrosis in atrial fibrillation. Am J Cardiol 111: 996-1001, 2013.

83. White SK, Sado DM, Fontana M, Banypersad SM, Maestrini V, Flett AS, Piechnik SK, Robson MD, Hausenloy DJ, Sheikh AM, *et al*: T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. JACC Cardiovasc Imaging 6: 955-962, 2013.

84. Neilan TG, Shah RV, Abbasi SA, Farhad H, Groarke JD, Dodson JA, Coelho-Filho O, McMullan CJ, Heydari B, Michaud GF, *et al*: The incidence, pattern, and prognostic value of left ventricular myocardial scar by late gadolinium enhancement in patients with atrial fibrillation. J Am Coll Cardiol 62: 2205-2214, 2013.

85. Ambale-Venkatesh B and Lima JA: Cardiac MRI: A central prognostic tool in myocardial fibrosis. Nat Rev Cardiol 12: 18-29, 2015.

86. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, McGregor C and Moon JC: Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: Preliminary validation in humans. Circulation 122: 138-144, 2010.

87. Kammerlander AA, Marzluf BA, Zotter-Tufaro C, Aschauer S, Duca F, Bachmann A, Knechtelsdorfer K, Wiesinger M, Pfaffenberger S, Greiser A, *et al*: T1 mapping by CMR imaging: From histological validation to clinical implication. JACC Cardiovasc Imaging 9: 14-23, 2016.

88. Ling LH, Kistler PM, Ellims AH, Iles LM, Lee G, Hughes GL, Kalman JM, Kaye DM and Taylor AJ: Diffuse ventricular fibrosis in atrial fibrillation: Noninvasive evaluation and relationships with aging and systolic dysfunction. J Am Coll Cardiol 60: 2402-2408, 2012.

89. Neilan TG, Mongeon FP, Shah RV, Coelho-Filho O, Abbasi SA, Dodson JA, McMullan CJ, Heydari B, Michaud GF, John RM, et al: Myocardial extracellular volume expansion and the risk of recurrent atrial fibrillation after pulmonary vein isolation. JACC Cardiovasc Imaging 7: 1-11, 2014.

90. McLellan AJ, Ling LH, Azzopardi S, Ellims AH, Iles LM, Sellenger MA, Morton JB, Kalman JM, Taylor AJ and Kistler PM: Diffuse ventricular fibrosis measured by T1 mapping on cardiac MRI predicts success of catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol 7: 834-840, 2014.

91. Guichard JB, Xiong F, Qi XY, L'Heureux N, Hiram R, Xiao J, Naud P, Tardif JC, Costa AD and Nattel S: Role of atrial arrhythmia and ventricular response in atrial fibrillation induced atrial remodeling. Cardiovasc Res: Jan 24, 2020 (Epub ahead of print).

92. Sasaki N, Okumura Y, Watanabe I, Nagashima K, Sonoda K, Kogawa R, Takahashi K, Iso K, Ohkubo K, Nakai T, et al: Transthoracic echocardiographic backscatter-based assessment of left atrial remodeling involving left atrial and ventricular fibrosis in patients with atrial fibrillation. Int J Cardiol 176: 1064-1066, 2014.

93. Avitall B, Bi J, Mykytsey A and Chicos A: Atrial and ventricular fibrosis induced by atrial fibrillation: Evidence to support early rhythm control. Heart Rhythm 5: 839-845, 2008.

94. Prabhu S, Costello BT, Taylor AJ, Gutman SJ, Voskoboinik A, McLellan AJA, Peck KY, Sugumar H, Iles L, Pathik B, et al: Regression of diffuse ventricular fibrosis following restoration of sinus rhythm with catheter ablation in patients with atrial fibrillation and systolic dysfunction: A substudy of the CAMERA MRI trial. JACC Clin Electrophysiol 4: 999-1007, 2018.

95. Schoonderwoerd BA, Smit MD, Pen L and Van Gelder IC: New risk factors for atrial fibrillation: Causes of 'not-so-lone atrial fibrillation'. Europace 10: 668-673, 2008.

96. Iwasaki YK, Kato T, Xiong F, Shi YF, Naud P, Maguy A, Mizuno K, Tardif JC, Comtois P and Nattel S: Atrial fibrillation promotion with long-term repetitive obstructive sleep apnea in a rat model. J Am Coll Cardiol 64: 2013-2023, 2014.

97. Neilan TG, Farhad H, Dodson JA, Shah RV, Abbasi SA, Bakker JP, Michaud GF, van der Geest R, Blankstein R, Steigner M, et al: Effect of sleep apnea and continuous positive airway pressure on cardiac structure and recurrence of atrial fibrillation. J Am Heart Assoc 2: e000421, 2013.

98. Pathak RK, Mahajan R, Lau DH and Sanders P: The implications of obesity for cardiac arrhythmia mechanisms and management. Can J Cardiol 31: 203-210, 2015.

99. Wijesurendra RS and Casadei B: Atrial fibrillation: Effects beyond the atrium? Cardiovasc Res 105: 238-247, 2015.

100. Rahmutula D, Marcus GM, Wilson EE, Ding CH, Xiao Y, Paquet AC, Barbeau R, Barczak AJ, Erle DJ and Olgin JE: Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1. Cardiovasc Res 99: 769-779, 2013.

101. Xiao HD, Fuchs S, Campbell DJ, Lewis W, Dudley SC Jr, Kasi VS, Hoit BD, Keshelava G, Zhao H, Capecchi MR and Bernstein KE: Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 165: 1019-1032, 2004.

102. Bauer P, regitz-zagrosek V, Kallisch H, Linz W, Schoelkens B, Hildebrandt AG and Fleck E: Myocardial angiotensin receptor type 1 gene expression in a rat model of cardiac volume overload. Basic Res Cardiol 92: 139-146, 1997.

103. Yeh YH, Kuo CT, Chang GJ, Qi XY, Nattel S and Chen WJ: Nicotinamide adenine dinucleotide phosphate oxidase 4 mediates the differential responsiveness of atrial versus ventricular fibroblasts to transforming growth factor-β. Circ Arrhythm Electrophysiol 6: 790-798, 2013.

104. Daccarett M, Badger TJ, Akoum N, Burgon NS, Mahnkopf C, Vergara G, Kholmovski E, McGann CJ, Parker D, Brachmann J, et al: Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. J Am Coll Cardiol 57: 831-838, 2011.

105. Akoum N, Fernandez G, Wilson B, Mcgann C, Kholmovski E and Marrouche N: Association of atrial fibrosis quantified using LGE-MRI with atrial appendage thrombus and spontaneous contrast on transesophageal echocardiography in patients with atrial fibrillation. J Cardiovasc Electrophysiol 24: 1104-1109, 2013.

106. King JB, Azadani PN, Suksaranjit P, Bress AP, Witt DM, Han FT, Chelu MG, Silver MA, Biskupiak J, Wilson BD, et al: Left atrial fibrosis and risk of cerebrovascular and cardiovascular events in patients with atrial fibrillation. J Am Coll Cardiol 70: 1311-1321, 2017.

107. Disertori M, Quintarelli S, Grasso M, Pilotto A, Narula N, Favalli V, Canclini C, Diegoli M, Mazzola S, Marini M, et al: Autosomal recessive atrial dilated cardiomyopathy with standstill evolution associated with mutation of natriuretic peptide precursor A. Circ Cardiovasc Genet 6: 27-36, 2013.

108. Fonseca AC, Alves P, Inácio N, Marto JP, Viana-Baptista M, Pinho-E-Melo T, Ferro JM and Almeida AG: Patients with undetermined stroke have increased atrial fibrosis: A cardiac magnetic resonance imaging study. Stroke 49: 734-737, 2018.

109. Tandon K, Tirschwell D, Longstreth WT Jr, Smith B and Akoum N: Embolic stroke of undetermined source correlates to atrial fibrosis without atrial fibrillation. Neurology 93: e381-e387, 2019.

110. Spronk HM, De Jong AM, Verheule S, De Boer HC, Maass AH, Lau DH, Rienstra M, van Hunnik A, Kuiper M, Lumeij S, et al: Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation. Eur Heart J 38: 38-50, 2017.

111. D'Souza A, Butcher KS and Buck BH: The multiple causes of stroke in atrial fibrillation: Thinking broadly. Can J Cardiol 34: 1503-1511, 2018.

112. Cai H, Li Z, Goette A, Mera F, Honeycutt C, Feterik K, Wilcox JN, Dudley SC Jr, Harrison DG and Langberg JJ: Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: Potential mechanisms for atrial thrombosis and stroke. Circulation 106: 2854-2858, 2002.

113. Friedrichs K, Klinke A and Baldus S: Inflammatory pathways underlying Atrial Fibrillation. Trends Mol Med 17: 556-563, 2011.

114. Korantzopoulos P, Letsas K, Fragakis N, Tse G and Liu T: Oxidative stress and atrial fibrillation: An update. Free Radic Res 52: 1199-1209, 2018.

115. Cao H, Wang J, Xi L, Røe OD, Chen Y and Wang D: Dysregulated atrial gene expression of osteoprotegerin/receptor activator of nuclear factor-κB (RANK)/RANK ligand axis in the development and progression of atrial fibrillation. Circ J 75: 2781-2788, 2011.

116. Pinto A, Tuttolomondo A, Casuccio A, Di Raimondo D, Di Sciacca R, Arnao V and Licata G: Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF). Clin Sci (Lond) 116: 781-789, 2009.

117. Li J, Solus J, Chen Q, Rho YH, Milne G, Stein CM and Darbar D: Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 7: 438-444, 2010.

118. Calvo D, Filgueiras-Rama D and Jalife J: Mechanisms and drug development in atrial fibrillation. Pharmacol Rev 70: 505-525, 2018.

119. Sardar MR, Saeed W and Kowey PR: Antiarrhythmic drug therapy for atrial fibrillation. Heart Fail Clin 12: 205-221, 2016.

120. Burashnikov A and Antzelevitch C: Novel pharmacological targets for the rhythm control management of atrial fibrillation. Pharmacol Ther 132: 300-313, 2011.

121. Novo G, Guttilla D, Fazio G, Cooper D and Novo S: The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS. Br J Clin Pharmacol 66: 345-351, 2008.

122. Li Y, Li W, Yang B, Han W, Dong D, Xue J, Li B, Yang S and Sheng L: Effects of Cilazapril on atrial electrical, structural and functional remodeling in atrial fibrillation dogs. J Electrocardiol 40: 100.e1-e6, 2007.

123. Belluzzi F, Sernesi L, Preti P, Salinaro F, Fonte ML and Perlini S: Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 53: 24-29, 2009.

124. Akashiba A, Ono H, Ono Y, Ishimitsu T and Matsuoka H: Valsartan improves L-NAME-exacerbated cardiac fibrosis with TGF-ß inhibition and apoptosis induction in spontaneously hypertensive rats. J Cardiol 52: 239-246, 2008.

125. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K and Saku K: Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 41: 2197-2204, 2003.

126. Nomura M, Kawano T, Nakayasu K and Nakaya Y: The effects of losartan on signal-averaged P wave in patients with atrial fibrillation. Int J Cardiol 126: 21-27, 2008.

127. Takemoto Y, Ramirez RJ, Kaur K, Salvador-Montañés O, Ponce-Balbuena D, Ramos-Mondragón R, Ennis SR, Guerrero-Serna G, Berenfeld O and Jalife J: Eplerenone reduces atrial fibrillation burden without preventing atrial electrical remodeling. J Am Coll Cardiol 70: 2893-2905, 2017.

128. Neefs J, van den Berg NW, Limpens J, Berger WR, Boekholdt SM, Sanders P and de Groot JR: Aldosterone pathway blockade to prevent atrial fibrillation: A systematic review and meta-analysis. Int J Cardiol 231: 155-161, 2017.

129. Rienstra M, Hobbelt AH, Alings M, Tijssen JGP, Smit MD, Brügemann J, Geelhoed B, Tieleman RG, Hillege HL, Tukkie R, *et al*: Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: Results of the RACE 3 trial. Eur Heart J 39: 2987-2896, 2018.

130. Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE and Schmieder RE: Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 55: 2299-2307, 2010.

131. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, *et al*: Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European society of cardiology (ESC). Eur Heart J 31: 2369-2429, 2010.

132. Chaugai S, Meng WY and Ali Sepehry A: Effects of RAAS blockers on atrial fibrillation prophylaxis: An updated systematic review and meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther 21: 388-404, 2016.

133. GISSI-AF Investigators, Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, Di Pasquale G and Tognoni G: Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360: 1606-1617, 2009.

134. Tveit A, Grundvold I, Olufsen M, Seljeflot I, Abdelnoor M, Arnesen H and Smith P: Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol 120: 85-91, 2007.

135. Shiroshita-Takeshita A, Brundel BJ, Burstein B, Leung TK, Mitamura H, Ogawa S and Nattel S: Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res 74: 75-84, 2007.

136. Kuhn EW, Liakopoulos OJ, Stange S, Deppe AC, Slottosch I, Choi YH and Wahlers T: Preoperative statin therapy in cardiac surgery: A meta-analysis of 90,000 patients. Eur J Cardiothorac Surg 45: 17-26, 2014.

137. Salvador-Montañés O, Gómez-Gallanti A, Garofalo D, Noujaim SF, Peinado R and Filgueiras-Rama D: Polyunsaturated Fatty acids in atrial fibrillation: Looking for the proper candidates. Front Physiol 3: 370, 2012.

138. Lee KW, Everett TH IV, Rahmutula D, Guerra JM, Wilson E, Ding C and Olgin JE: Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 114: 1703-1712, 2006.

139. Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, *et al*: Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): A report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 61: 1935-1944, 2013.

140. Holmqvist F, Kesek M, Englund A, Blomström-Lundqvist C, Karlsson LO, Kennebäck G, Poçi D, Samo-Ayou R, Sigurjónsdóttir R, Ringborn M, *et al*: A decade of catheter ablation of cardiac arrhythmias in Sweden: Ablation practices and outcomes. Eur Heart J 40: 820-830, 2019.

141. Kottkamp H: Human atrial fibrillation substrate: Towards a specific fibrotic atrial cardiomyopathy. Eur Heart J 34: 2731-2738, 2013.

142. Kottkamp H and Schreiber D: The substrate in 'early persistent' atrial fibrillation: Arrhythmia induced, risk factor induced, or from a specific fibrotic atrial cardiomyopathy? JACC Clin Electrophysiol 2: 140-142, 2016.

143. Oakes RS, Badger TJ, Kholmovski EG, Akoum N, Burgon NS, Fish EN, Blauer JJ, Rao SN, DiBella EV, Segerson NM, *et al*: Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation 119: 1758-1767, 2009.

144. Rolf S, Kircher S, Arya A, Eitel C, Sommer P, Richter S, Gaspar T, Bollmann A, Altmann D, Piedra C, *et al*: Tailored atrial substrate modification based on low-voltage areas in catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol 7: 825-833, 2014.

145. Kapa S, Desjardins B, Callans DJ, Marchlinski FE and Dixit S: Contact electroanatomic mapping derived voltage criteria for characterizing left atrial scar in patients undergoing ablation for atrial fibrillation. J Cardiovasc Electrophysiol 25: 1044-1052, 2014.

146. Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, Kholmovski E, Burgon N, Hu N, Mont L, *et al*: Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: The DECAAF study. JAMA 311: 498-506, 2014.

147. Canpolat U, Oto A, Hazırolan T, Sunman H, Yorgun H, Şahiner L, Kaya EB and Aytemir K: A prospective DE-MRI study evaluating the role of TGF-β1 in left atrial fibrosis and implications for outcomes of cryoballoon-based catheter ablation: New insights into primary fibrotic atriocardiomyopathy. J Cardiovasc Electrophysiol 26: 251-259, 2015.

148. McGann C, Akoum N, Patel A, Kholmovski E, Revelo P, Damal K, Wilson B, Cates J, Harrison A, Ranjan R, *et al*: Atrial fibrillation ablation outcome is predicted by left atrial remodeling on MRI. Circ Arrhythm Electrophysiol 7: 23-30, 2014.

149. Stiles MK, John B, Wong CX, Kuklik P, Brooks AG, Lau DH, Dimitri H, Roberts-Thomson KC, Wilson L, De Sciscio P, *et al*: Paroxysmal lone atrial fibrillation is associated with an abnormal atrial substrate: Characterizing the 'second factor'. J Am Coll Cardiol 53: 1182-1191, 2009.

150. Kottkamp H, Berg J, Bender R, Rieger A and Schreiber D: Box isolation of fibrotic areas (BIFA): A patient-tailored substrate modification approach for ablation of atrial fibrillation. J Cardiovasc Electrophysiol 27: 22-30, 2016.

151. Yamaguchi T, Tsuchiya T, Nakahara S, Fukui A, Nagamoto Y, Murotani K, Eshima K and Takahashi N: Efficacy of left atrial voltage-based catheter ablation of persistent atrial fibrillation. J Cardiovasc Electrophysiol 27: 1055-1063, 2016.

152. Yagishita A, Gimbel JR, DE Oliveira S, Manyam H, Sparano D, Cakulev I, Mackall J and Arruda M: Long-term outcome of left atrial voltage-guided substrate ablation during atrial fibrillation: A novel adjunctive ablation strategy. J Cardiovasc Electrophysiol 28: 147-155, 2017.

153. Jadidi AS, Lehrmann H, Keyl C, Sorrel J, Markstein V, Minners J, Park CI, Denis A, Jaïs P, Hocini M, *et al*: Ablation of persistent atrial fibrillation targeting low-voltage areas with selective activation characteristics. Circ Arrhythm Electrophysiol 9: e002962, 2016.

154. Yang G, Yang B, Wei Y, Zhang F, Ju W, Chen H, Li M, Gu K, Lin Y, Wang B, *et al*: Catheter ablation of nonparoxysmal atrial fibrillation using electrophysiologically guided substrate modification during sinus rhythm after pulmonary vein isolation. Circ Arrhythm Electrophysiol 9: e003382, 2016.

155. Kottkamp H, Schreiber D, Moser F and Rieger A: Therapeutic approaches to atrial fibrillation ablation targeting atrial fibrosis. JACC Clin Electrophysiol 3: 643-653, 2017.

156. Jadidi AS, Cochet H, Shah AJ, Kim SJ, Duncan E, Miyazaki S, Sermesant M, Lehrmann H, Lederlin M, Linton N, *et al*: Inverse relationship between fractionated electrograms and atrial fibrosis in persistent atrial fibrillation: Combined magnetic resonance imaging and high-density mapping. J Am Coll Cardiol 62: 802-812, 2013.

157. Gal P and Marrouche NF: Magnetic resonance imaging of atrial fibrosis: Redefining atrial fibrillation to a syndrome. Eur Heart J 38: 14-19, 2017.

158. Fochler F, Yamaguchi T, Kheirkahan M, Kholmovski EG, Morris AK and Marrouche NF: Late gadolinium enhancement magnetic resonance imaging guided treatment of post-atrial fibrillation ablation recurrent arrhythmia. Circ Arrhythm Electrophysiol 12: e007174, 2019.

159. Boyle PM, Zghaib T, Zahid S, Ali RL, Deng D, Franceschi WH, Hakim JB, Murphy MJ, Prakosa A, Zimmerman SL, *et al*: Computationally guided personalized targeted ablation of persistent atrial fibrillation. Nat Biomed Eng 3: 870-879, 2019.

160. Sohns C and Marrouche NF: Atrial fibrillation and cardiac fibrosis. Eur Heart J 41: 1123-1131, 2020.

161. Kottkamp H, Bender R and Berg J: Catheter ablation of atrial fibrillation: How to modify the substrate? J Am Coll Cardiol 65: 196-206, 2015.